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Saliva testing has attracted great interest in the forensic scientific landscape 
recently, especially among institutions or legal authorities interested in determining 
drug concentrations (for application in the workplace, drug driving, legal issues 
associated with drug testing, and pharmacokinetics of selected drugs). Indeed, it 
has been established that oral fluid is an adequate alternative biological matrix to 
blood for the determination of xenobiotics and/or drugs of abuse and/or metabo-
lites both in living and deceased individuals. The concentration of a detectable 
substance in saliva is generally proportional to the free fraction of the drug present 
in plasma; this measurement therefore makes it possible to correlate the concentra-
tion of the substance and its pharmacological effects on the individual. The purpose 
of this chapter is to examine the main analytical techniques developed thus far in 
saliva drug testing, from screening to confirmatory analysis, taking into account 
the interpretation of cut-off levels. Both well-defined and potentially problematic 
issues are highlighted from medico-legal and toxicological perspectives.
Keywords: salivary analysis, drugs, analytical techniques, legal medicine, 
forensic toxicology
1. Introduction
Detecting the presence of drugs or their metabolites in biological material 
requires different approaches and methods, depending on the purpose of the 
investigation and specific legal requirements. In the forensic toxicology field, 
multiple biological matrices are commonly used as diagnostic tools (such as blood, 
urine, keratin matrices, oral fluid, etc.) and the respective results, either alone or 
in combination with each other, provide useful elements for a correct diagnosis. 
An investigation may be prompted by various concerns: suitability to drive, profes-
sional driver suitability, employee and work suitability, suitability for gun permit, 
suitability for specific competition and/or contractual rules, diagnosis of use/abuse 
(also in the contexts of custody of minors and international adoptions), diagnosis 
of drug addiction, and diagnosis of intoxication in living or dead people.
Technical choices are based on these premises and purposes. For example, 
urine testing can typically determine the “recent” consumption of substances of 
abuse (with a temporal detection window of hours or even days depending on the 
pharmacokinetic characteristics of the substance in question). This sample can also 
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be used to determine chronic drug use if the analysis is extended to several samples 
collected on different days and “by surprise” (i.e. with the shortest possible notice 
given to the interested party, not exceeding 24 hours). Chronic use, as well as previ-
ous patterns of use/abuse, can be verified by analysis of the hair matrix too.
In cases where it is necessary to quickly evaluate degree of substance intoxication 
(for example in an emergency situation) blood testing is particularly useful. Even 
so, over the past few years oral fluid has been increasingly studied as an alternative 
matrix of choice, and a number of reviews and papers have recently focused on 
various aspects of drug testing using oral fluid, although it has a shorter detection 
window than blood (Figure 1). Consideration should be given to the importance 
of oral fluid as a clinical diagnostic [1] and forensic tool and its relevance for a 
range of applications including workplace drug testing [2], drug driving [3], legal 
issues associated with drug testing [4], pharmacokinetics of selected drugs [5], and 
therapeutic drug monitoring (TDM) [6].
Regarding its composition, saliva is a very dilute fluid. Its major constituent is 
water (> 97%); other components include electrolytes, immunoglobins, enzymes and 
proteins. In normal conditions, healthy adults produce approximately 500–1500 mL 
saliva in 24 hours through the submandibular gland (about 65%), the parotid 
gland (23%) and the sublingual gland (4%), along with many other small glands 
distributed in the oral cavity (about 8%). Products of the salivary glands can be 
classified into four major components with different functions: mucus that serves as 
a lubricant; amylase, an enzyme that initiates the digestion of starch; lingual lipase, 
an enzyme that begins the fat digestion process; and a slightly alkaline electrolyte 
solution that moistens food so that it can be swallowed easily.
The most abundant salivary electrolytes are sodium, potassium, chloride and 
bicarbonate, while calcium, magnesium and phosphate are present in lesser concen-
trations. Other salivary constituents include substances transported from the blood 
through the gland into saliva [7].
Salivation can be stimulated or reduced by several factors. Electrolyte concen-
trations and volume of saliva produced are influenced by the time of day and type 
of salivation stimulus. In fact, the volume and composition of oral fluid can vary 
during the day and over time in each individual. Therefore, it can be said that its 
composition varies continuously, both quantatively and qualitatively [8]. When 
salivary constituents need to be identified, it should be emphasised that the results 
will depend on the subject’s cooperation, psychological status, medication use, 
method of sampling and time of day.
Saliva has a slightly more acidic pH (6 to 7) than that of blood, and therefore all 
lipophilic psychoactive substances, with a weak basic nature, low molecular weight 
and blood protein binding of less than 50%, are preferentially excreted in saliva by 
passive diffusion of the free fraction of the substance in its ionised form. Moreover, 
the pH of saliva can change from being slightly acidic at rest, to basic (pH 8) at 
Figure 1. 
Drug detection times in different matrices.
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ultimate stimulation. Amylase and mucus also increase in concentration after 
stimulation [8].
The first guidelines for the analysis of substances of abuse in saliva were 
proposed in 2004 in the United States by the “Substance Abuse and Mental 
Health Service Administration” (SAMHSA) [9] and were mainly intended for 
analyses carried out in the workplace to determine the possible use of substances. 
Subsequently, the “European Workplace Drug Testing Society” (EWDTS) [10] also 
drafted European guidelines, again oriented to analyses in workplaces. SAMHSA 
published its final Mandatory Guidelines for Federal Workplace Drug Testing 
Programs using Oral Fluid on October 25, 2019 in the Federal Register [11]. The 
new regulations only apply to federal workplaces, at the time of writing, but the 
impact is sure to reach beyond the initial scope of these regulations.
2. Drug transfer from blood to saliva
The most common routes for a drug to migrate to saliva are passive transcellular 
diffusion, ultrafiltration, active transport and passive diffusion.
a. Passive transcellular diffusion: highly lipid-soluble substances may pass 
through the capillary wall, basement membrane and acinar cell of the secretory 
end-piece, with the lipid layer of the epithelial cell wall providing the rate-
limiting barrier. The same mechanism would probably enable these molecules 
to pass through the cells lining the ducts of the gland. The salivary concentra-
tions of the lipid-soluble, unconjugated steroids such as oestriol, cortisol 
and testosterone approximate the unbound plasma concentrations. But, the 
concentration of the lipid-insoluble, conjugated steroid dehydroepiandroster-
one sulphate is approximately 1% of the unbound plasma concentration [12].
b. Ultrafiltration (or paracellular transport): small polar molecules such as 
glycerol and sucrose enter saliva. The saliva/plasma (S/P) ratios of several 
small polar, lipid-insoluble compounds are plotted as a function of their 
molecular weight (MW). This mechanism is restricted to compounds with a 
MW of less than about 300 Da, and even those with a MW of about 150 Da are 
only filtered to a minimal extent. Furthermore, the flow rate of saliva should 
not affect S/P ratios if diffusion is rapid and passive.
c. Active transport mechanism: clearly operates for many electrolytes and 
for some proteins such as IgA. This mechanism has also been proven for 
some drugs. Lithium (MW = 7 Da) would be expected to appear in saliva by 
ultrafiltration. However, the findings of a S/P ratio of more than two indi-
cates an active secretory mechanism [13]. Borzelleca (1965) [14] investigated 
whether penicillin and tetracycline were secreted in saliva. The secretion of 
these antibiotics in saliva appeared to be dependent on the concentration in 
the blood. Since the secretion of penicillin by the salivary apparatus and by 
the kidney were both inhibited by probenecid, an inhibitor of the active renal 
pathway, at least a part of the penicillin secretion in saliva involved an active 
mechanism.
d. Passive diffusion process: is characterised by the transfer of drug molecules 
down a concentration gradient with no expenditure of energy. The rate of 
diffusion of a drug is a function of the concentration gradient, the surface area 
over which the transfer occurs, the thickness of the membrane, and a diffusion 
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constant that depends on the physico-chemical properties of each drug [15]. 
The variables which influence this type of transport are listed in Table 1 
(Landon and Mahmod, 1982) [16].
Salivary secretion is a reflex response controlled by both parasympathetic and 
sympathetic secretomotor nerves. This is an important factor influencing oral fluid 
availability and potential drug concentrations. Taking medication which affects 
either the central nervous system or the peripheral nervous system (or medication 
which mimics the latter as a side effect) alters salivary composition and salivary 
volume. Therefore, patients suffering from systemic diseases may show alterations 
in salivary gland secretion and electrolyte concentrations. Finally, diet and age also 
have an impact on composition and volume of saliva [8].
3. Methods and techniques
3.1 The sampling
It is essential to prepare Standard Operating Procedures (SOPs) relating to the 
collection and storage of the oral fluid sample, as well as the training of person-
nel assigned to take and ship the sample to the laboratory where the toxicological 
analysis will be carried out. It follows that it is essential to document:
• respect for the privacy and security of the person undergoing analytical 
assessment;
• the identity of the person undergoing analytical assessment;
• the location where the sample of oral fluid has been collected;
• that no falsification or tampering of the sample has taken place;
RELATING TO DRUG
Lipid-solubility
Acidic or basic, and the pKa





Saliva-binding proteins - usually minimal
Enzymes in saliva capable of metabolising the drug
RELATING TO THE CIRCULATING DRUG LEVEL IN THE FREE (NONPROTEIN-BOUND) FORM
Dose and clearance of drug
Nonprotein-bound blood level
Table 1. 
Factors influencing passive diffusion of a drug from blood to saliva.
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• that the informed consent form has been completed in its entirety by the 
person undergoing the analytical assessment (unless there is a formal mandate 
from the Legal Authority);
• the use of particular medicines that may interfere with the analytical results;
• the traceability of the sample through appropriate records of its movement, 
from the place of sampling to the laboratory that receives it, including the 
identity records of the personnel authorised to handle it.
Neat oral fluid can be collected from expectoration (or spitting), but this is 
relatively viscous and can therefore be challenging to work with and analyse in 
the laboratory. It may also be contaminated with food and oral debris, which 
makes centrifugation essential. In addition, sensitive detection techniques are 
required, because the volume collected will often be less than 1 mL. Normally, 
the absorbent foam swab or pad used to collect the oral fluid is added to a dilu-
ent. After mixing, the solution is ready for drug analysis. Other devices involve 
squeezing absorbed oral fluid from a pad or foam directly onto the drug-detec-
tion device, a process that can take one to three minutes. A number of devices 
incorporate some form of indicator to show when an adequate amount of oral 
fluid has been collected [17].
A number of drugs affect the secretion of oral fluid [8], mostly cannabis and 
amphetamines, including designer drugs such as MDMA. Other drugs include the 
sedating antihistamines, antipsychotic drugs, anticholinergic drugs and several 
antidepressants. Less commonly used drugs increase saliva flow and these include 
clonidine, pilocarpine and beta-2 stimulants (salbutamol, terbutaline, etc). Overall, 
there is significant intra- and inter-subject variation in relation to drug concentra-
tions depending on the technique used, the physiology of the person and the factors 
affecting drug concentration in oral fluid.
3.2 Analytical techniques
An important aspect to consider is the choice of analytical technique used for the 
detection of drugs and metabolites in saliva. A fundamental element is the certainty 
and reliability of the results, from both qualitative and quantitative perspectives. The 
results of quantitative determination, though, are not easy to interpret as the infor-
mation that makes it possible to trace the metabolic process is often unavailable (e.g. 
time the drug was taken, amount of active ingredient, and route of administration).
In many forensic contexts, oral fluid is analysed with screening methods. The 
semiquantitative results obtained must be validated by confirmatory techniques, 
such as liquid chromatography combined with mass spectrometry [18]. Oral fluids 
(OF) have been recently introduced as a biological matrix useful for roadside 
testing to determine illicit drug use because the time course of drugs in oral fluid 
may resemble that of plasma. Moreover, OF can be considered a valid alternative 
specimen for confirmation testing because drugs are excreted in saliva mainly as 
parent compounds [19–21]. In fact police officers, without medical supervision, are 
not authorised to employ invasive methods but they can collect OF samples. A very 
comprehensive review of the analysis of drugs of abuse in OF was conducted by 
Reinstadler et al. [22]. Other studies [23] have highlighted the importance of both 
the sample treatment process and the use of hyphenated instruments in obtaining 
analytical performances that satisfy current regulations in terms of sensitivity, 
selectivity and fast confirmatory analysis.
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3.2.1 On-site screening test
Recent data have shown improvements in the effectiveness of on-site drug 
testing using oral fluid, and significant progress has been made in terms of sample 
collection and accuracy of analysis [24].
A number of field drug testing devices are available and used in many coun-
tries to perform on-site testing on oral fluids in the context of Driving Under the 
Influence of Drugs (DUID) [25]. For example, DrugWipe® is an immunochro-
matographic test strip, based on the Frontline urine test strip from Boehringer 
Mannheim. A pink colour in the test window indicates the presence of the analyte 
in question, but different devices are normally required to detect the various classes 
of drugs of abuse. However, a recent version of this device, DrugWipe 5A, is capable 
of indicating the simultaneous use of cannabis, amphetamine, methamphetamine, 
ecstasy, cocaine, and opiates [26]. A recent study investigated the reliability of 
DrugWipe 5A in establishing exposure to principal drugs of abuse (cannabis, 
amphetamines, cocaine, and opiates) using oral fluid specimens by comparing the 
on-site results with headspace solid-phase microextraction (HS-SPME) gas chro-
matography–mass spectrometry (GC–MS) analyses on extractions from the sample 
collection pad [27].
Another point of collection test, Rapid STAT®, has broken new ground by 
combining the convenience of oral fluid collection, surface wipe testing or pure 
substance measurements with the sensitivity, accuracy and precision of a laboratory 
based test, with speedy results (in a few minutes).
Table 2 shows the recommended minimum detectable concentrations of drugs 
in oral fluid according to SAMHSA and European Union roadside assessment 
testing study (ROSITA) cut-off levels [28].
3.2.2 Laboratory screening test
The enzyme-linked immunosorbent assay (ELISA) is a sensitive and versatile 
test used in many fields to detect and measure substances in biological samples 
(Figure 2). For almost 50 years it has remained a trusted testing technique for 
everything from food allergen detection to medical screening for various illnesses. 
For the toxicology market specifically, ELISA is an excellent and cost-effective 
solution which meets high-throughput screening (HTS) needs. The procedure is 
simple and easily automated or it can be conducted by a laboratory technician. It 
basically works around the principle of competition between two substances in a 
given sample: an enzyme conjugate such as horseradish peroxidase (HRP) is used to 
compete with a target substance for a limited number of specific binding sites on a 
precoated microplate.








Recommended minimum detectable concentrations of drugs in oral fluid – Instrumental devices field testing.
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The different available types of ELISAs provide a reliable means for screening 
oral fluid. In general these work adequately for amphetamines [29], buprenorphine, 
cocaine [30], methadone [31], and other opioids [32]. Cannabis may pose more 
difficulties, particularly if the immunoassay has little cross-reactivity to tetrahydro-
cannabinol (THC), the main psychoactive component of the drug. Even so, enzyme 
immunoassay has been successfully used for cannabis; the same applies to benzodi-
azepines despite their low oral fluid concentrations [33].
3.2.3 Confirmatory analysis
Confirmatory techniques for drugs in oral fluid [20] are mostly adapted from 
those used in the analyses of blood or plasma/serum specimens. Recovery of drugs 
is not typically a limiting factor, considering the higher water content and lower 
protein levels of oral fluid compared to blood. However, the sample volume of 
oral fluid will be smaller, with potentially lower concentrations, which means that 
more adjustments are required to analytical techniques. Indeed, in saliva analysis 
the detection or quantification limit for drugs is very much determined by the type 
of screening test and its application. The confirmation method must be able to 
produce an analytical result that is optimally independent from that of the screen-
ing. Therefore, it must be based on different physico-chemical principles and have 
superior analytical selectivity and sensitivity. In this regard, a quantitative confir-
matory method capable of reaching a lower limit of quantification (LLOQ ) equal to 
at least half the cut-off of the screening method is considered acceptable. The use 
of a confirmatory method which is based on the measurement of a similar analyti-
cal signal is not acceptable since it is highly correlated to that of the screening (e.g. 
confirmation of a given immunochemical with another immunochemical method). 
The use of an identical chromatographic technique to confirm a set of data obtained 
by chromatography is acceptable if the detection technique combined with chroma-
tography changes.
The use of a chromatographic technique to confirm screening data obtained by 
chromatography with the same detection system is allowed only if the two separation 
techniques produce poorly correlated results (for example, two series of significantly 
different retention times, with the use of columns of different polarity or selectiv-
ity, etc). However, in the forensic toxicological field, chromatographic separation is 
always necessary in a confirmatory method; the general consensus of the interna-
tional scientific community is that mass spectrometry (MS) with its many method-
ological possibilities can be combined with a chromatographic separation technique 
such as gas chromatography (GC), high pressure liquid chromatography (HPLC) or 
capillary electrophoresis (EC) for confirmatory analysis (Figure 3). Many methods 
Figure 2. 
Fully automated Elisa analyser.
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use LC–MS as distinct from GC–MS to cater for the lower sample volumes and low 
detection limits, although a number of GC–MS techniques have exhibited adequate 
sensitivity [34].
4. Medico-legal and toxicological issues
4.1 Saliva versus blood
Intra-individual variability of the S/P ratio has been demonstrated for a number 
of drugs administered orally or intravenously [35]. Following the uptake of an orally 
applied substance in the intestine, arterial blood has a higher concentration than 
venous blood (positive arteriovenous difference). If the substance is completely 
absorbed but not significantly metabolised in a particular organ, the situation is 
reversed: the substance rediffuses from the cells into the blood (negative arteriove-
nous difference in the elimination phase). The various organs can be classified into 
two groups: those with a high blood flow (e.g. liver, kidney, brain, salivary glands), 
and those with a relatively low blood flow (e.g. skin, resting skeletal muscle, fat). 
In pharmacokinetics the first group of highly perfused organs is included in the 
central compartment, while the second group of less perfused organs belongs to the 
peripheral compartment. This must be taken into account when saliva concentra-
tions are compared with blood concentrations from cubital veins in the peripheral 
compartment. In any case, salivary glands have a high blood flow, which means that 
the arteriovenous difference of freely diffusible substances is relatively small, with 
a ratio close to 1.0. Poor correlations between the two compartments have been 
documented in the literature, but neglect of the phenomenon described can only 
partly account for this [36].
Some comparative studies [37, 38] have found that drug concentrations in oral 
fluid cannot be used to accurately estimate drug concentrations in blood. A posi-
tive result in an oral fluid test may certainly confirm recent drug use, but it may 
only provide a semiquantitative assessment of the drug concentration in the blood 
(and only for some drugs). For psychiatric patients, oral fluid testing may be used 
as a non-invasive technique for evaluating substance use. In the case of drivers 
suspected of driving under the influence of drugs, oral fluid may be used for initial 
on-site screening tests (afterwards, it may be decided that a blood sample should be 
taken for forensic drug analysis).
Figure 3. 
Ultra-high performance liquid chromatography.
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Wille et al. (2009) [37] analysed blood and saliva samples by gas chromatogra-
phy–mass spectrometry (GC–MS) or liquid chromatography-mass spectrometry 
(LC–MS). Scatter plots and trend lines of the blood and oral fluid concentrations 
were created and the median, mean, range, and standard deviation (SD) of the oral 
fluid to blood (OF/B) ratios were calculated for different classes of drugs, including 
amphetamines, benzodiazepines, cocaine, opiates, and delta9-2 tetrahydrocannabi-
nol. The ratios found in this study were in line with previously published results, 
but the range was wider. The OF/B ratios of drugs of abuse such as amphetamines, 
cocaine, and opiates were > 1 [amphetamine: median (range) 13 (0.5-182), methy-
lenedioxyamphetamine: 4 (1-15), methylenedioxymethamphetamine: 6 (0.9-88), 
methamphetamine: 5 (2-23), cocaine: 22 (4-119), benzoylecgonine: 1 (0.2-11), 
morphine: 2 (0.8-6), and codeine: 10 (0.8-39)]. Unsurprisingly, the ratios for ben-
zodiazepines were considerably lower: given their high protein binding and weak 
acidity, benzodiazepines typically have low oral fluid concentrations [diazepam: 
0.02 (0.01-0.15), nordiazepam: 0.04 (0.01-0.23), oxazepam: 0.05 (0.03-0.14), and 
temazepam: 0.1 (0.06-0.54)]. For tetrahydrocannabinol, an OF/B ratio of 15 was 
found (range 0.01-569). The variability of the OF/B ratios in suspected drugged 
drivers was clearly mirrored in the data. Be that as it may, blood concentrations 
could not be reliably calculated from oral fluid concentrations, due to the wide 
range of ratios.
Gjerde H et al. (2010) [38] analysed 90 pairs of blood and oral fluid specimens 
from patients undergoing acute psychiatric treatment and 22 pairs of blood and oral 
fluid specimens from suspected drugged drivers, with the aim of comparing drug 
concentrations between the two biological matrices. The median oral fluid/blood 
drug concentration ratios for the most prevalent drugs were 0.036 diazepam, 0.027 
nordiazepam, 7.1 amphetamine, 2.9 methamphetamine, 5.4 codeine, 1.9 morphine, 
and 4.7 tetrahydrocannabinol. For the six most prevalent drugs, the correlation 
coefficients between drug concentrations in oral fluid and blood ranged from 0.15 
to 0.96. The results, therefore, showed large interindividual variations in drug 
concentration ratios between oral fluid and blood. This wide distribution of OF/B 
ratios indicated that drug concentrations in oral fluid may not be used to reliably 
estimate drug concentrations in blood.
Such analytical variability could cause controversy in the judicial field, especially 
when the values obtained from saliva are only slightly higher than the cut-off levels 
established by the law of various countries.











Δ9- Tetrahydrocannabinol [49] 1.2
Table 3. 
Average oral fluid to blood concentration ratios for selected drugs.
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Table 3 shows the average values of oral fluid to blood concentration ratios 
of selected drugs, based on various pharmacokinetic studies; the average ratios 
change depending on a number of factors, such as pH of oral fluid, protein bind-
ing and degree of contamination of the membranes in the oral cavity by recently 
consumed drug.
4.2 Cut-off levels and analytical interpretation
Interpretation of oral fluid drug test results depends to some extent on the 
purpose of testing. An employer may decide to implement a workplace drug 
testing programme primarily to detect drug abuse among employees (or even job 
applicants), especially regarding safety-sensitive positions or following a safety 
incident or accident. Random workplace testing could also serve as a deterrent 
to substance misuse in the general workforce. Drug treatment specialists carry 
out drug testing to foster drug abstinence and compliance with programme 
requirements. Numerous factors must be considered when interpreting drug test 
results. During this process, complex questions may be posed, depending on the 
nature of the drug-testing programme, and sometimes the answers sought go 
beyond reasonable scientific certainty. Patterns of metabolic disposition should be 
understood for each class of drugs. Of course, the interpretation of oral fluid tests 
requires knowledge of the unique features of this biological matrix, along with a 
thorough understanding of: the chemical and physiological factors that affect drug 
transfer into oral fluid; analytical factors; kinetic aspects of drug disposition; drug 
metabolic patterns; and potential risks of oral contamination and passive exposure. 
Generally speaking, it has been shown that oral fluid tests are most useful in the 
detection of recent drug use [50].
The use of a screening method can be justified in a forensic toxicology labora-
tory when there is a need to analyse a large number of samples in a short time and at 
low costs, with the advantages of high or total automation. Screening methods usu-
ally employ colorimetric, enzymatic, and immunochemical techniques. However, 
screening methods are characterised by low specificity (qualitative data) and high 
inaccuracy (quantitative data), particularly when several chemical species can be 
detected in the sample but not discriminated by the method (e.g. an unchanged 
compound and its metabolites, or various types of similar species of compounds). 
Given their intrinsic characteristics, these methods exclusively produce a presump-
tive result, that is to say the probable negativity (absence) or positivity (presence, 
better defined as “non-negativity”) of the sample with respect to an analyte, or 
more often a class of substances, relative to a cut-off value set by the method. In any 
case, whatever the analytical specificity of the screening method, a positive result 
obtained through a single screening test cannot have forensic validity. It is therefore 
essential that this result is verified by a confirmatory analysis on a new sample rate.
The results of a quantitative analysis must be expressed in a uniform unit of 
measurement, so as to exclude interpretative doubts, directly comparable with any 
reference values (cut-off) and accepted by the International System of Units (SI). 
The uncertainty associated with the measurement performed must be indicated; 
at the same time, the comparison with threshold or reference values must take into 
account this uncertainty. Tables 4 and 5 show the recommended cut-off levels of 
oral fluid tests according to EWDTS and SAMHSA guidelines.
Drugs and metabolites can be detected for a period of several hours to several 
days following drug exposure. Their concentrations in oral fluid are generally 
related to content in blood, but may also be present as residual drug in the oral 
cavity [11].
In what follows, descriptions of the main drugs of abuse are given [50].
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AMPHETAMINE: a synthetic substance related to natural sympathomimetic 
amines with central nervous stimulant activity. Amphetamine appears rapidly 
in oral fluid following administration and parallels plasma drug concentrations. 
Amphetamine is also produced as a metabolite of methamphetamine and from a 
variety of pharmaceutical products. A positive test result for amphetamine indicates 
amphetamine use; determination of d/l-isomer ratio should rule out the possibility 
of mystification with another drug.
METHAMPHETAMINE: a synthetic sympathomimetic amine with central 
nervous stimulant activity similar to amphetamine but with more lasting effects. 
It is misused in numerous ways including smoking, snorting, injecting, and oral 
administration. Methamphetamine and amphetamine appear rapidly in plasma and 
oral fluid following administration. Determination of d/l-isomer ratio rules out the 
possibility that methamphetamine presence is due to the metabolism of another 
drug or use of an over-the-counter nasal inhaler. A positive test result for meth-
amphetamine and amphetamine (methamphetamine < amphetamine) indicates 
possible combined use of methamphetamine and amphetamine.
METHYLENEDIOXYMETHAMPHETAMINE (MDMA): a synthetic, 
ring-substituted amphetamine derivative. N-demethylation of MDMA yields 
3,4-methylenedioxyamphetamine (MDA), an active metabolite exhibiting 
similar pharmacological properties as the parent drug. O-demethylenation of 
MDMA and MDA produces 3,4-dihydroxymethamphetamine (HHMA) and 
Drug Screening Cut-off (ng/mL) Confirmation Cut-off 
(ng/mL)
OPIATES













Cocaine Cocaine + metabolites 30 8
Benzoylecgonine 8
AMPHETAMINE AND CONGENERS





THC THC 10 2
Table 4. 
Recommended maximum screening and confirmation cut-off values for oral fluid tests in the workplace 



























Initial Test Analyte Screening Cut-off (ng/mL) Confirmatory Test Analyte Confirmatory Test Cut-off (ng/mL)
THC (Cannabis) 4 THC 2
Cocaine/Benzoylecgonine 15 Cocaine/Benzoylecgonine 8
8




Oxycodone/Oxymorphone 30 Oxycodone/Oxymorphone 15
15
6-Acetylmorphine (heroin) 4 6-Acetylmorphine 2
Phencyclidine (PCP) 10 Phencyclidine 10
Amphetamine/Methamphetamine 50 Amphetamine/Methamphetamine 25
25




Cut-off levels of oral fluid testing according to SAMHSA oral fluid guidelines [11] (effective January 1, 2020).
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3,4-dihydroxyamphetamine (HHA), respectively. MDMA is typically administered 
orally and reaches maximal blood concentrations in approximately 2 hours. Oral 
fluid concentrations of MDMA are highly correlated with plasma MDMA. Oral 
fluid concentrations of MDMA are an order of magnitude higher than in plasma; 
this is attributed to the high pKa of MDMA and low plasma–protein binding. A 
positive test result for MDMA (no MDA) indicates illicit MDMA use; a positive test 
result for MDMA and MDA suggests illicit MDMA use (presence of MDA probably 
due to metabolism of MDMA to MDA but if MDA ≥ MDMA, a combined use of 
illicit MDMA and illicit MDA is admissible).
3,4-METHYLENEDIOXYAMPHETAMINE (MDA): a synthetic, ring-substi-
tuted amphetamine derivative. MDA has been reported to appear in oral fluid fol-
lowing the administration of MDMA in concentrations representing approximately 
4–5% of MDMA. Possible sources of MDA: illicit MDA, metabolite of illicit MDMA, 
metabolite of illicit MDEA. However, the confirmed presence of HHA and/or HMA 
in oral fluid would be useful to substantiate MDA use.
3,4-METHYLENEDIOXYETHYLAMPHETAMINE (MDEA): a synthetic ana-
logue which is generated when an ethyl group is substituted for the methyl group 
of MDMA. MDEA is metabolised by O-demethylenation and by N-dealkylation 
of the ethyl-group. The major metabolite is formed by O-demethylenation to yield 
N-ethyl-4-hydroxy-3-methoxyamphetamine (HME); N-dealkylation leads to the 
formation of the active metabolite MDA. A positive test result for MDEA without 
MDA means illicit MDEA use, otherwise (in co-presence with MDA) combined use 
or an initiated metabolism of MDEA.
DELTA-9-TETRAHYDROCANNABINOL (THC): a naturally occurring psy-
choactive constituent of Cannabis sativa. THC appears rapidly in plasma following 
the smoking of cannabis products and is found in oral fluid following smoked and 
oral ingestion. According to several studies, THC is more highly present in oral 
fluid than blood, primarily as a result of deposition in the oral cavity. THC tends to 
decline in a similar manner to plasma concentrations.
COCAINE: a natural stimulant compound made from the leaves of the coca 
plant. Cocaine has a short half-life (approximately 1 hour) and is rapidly hydrolysed 
by hepatic esterases to benzoylecgonine (BZE) and ecognine methyl ester (EME). 
Cocaine and its metabolites appear rapidly in oral fluid following all routes of 
administration. Cocaine concentrations decrease rapidly within approximately 
1 hour; thereafter, oral fluid concentrations appear to decline in parallel with 
concentrations of the drug in the blood. If cocaine concentration > BZE concentra-
tion: cocaine has probably been taken within the past 2–8 hours; cocaine concentra-
tion < BZE concentration: cocaine use in the past 12 hours for occasional users and 
48 hours for daily users.
HEROIN: a semisynthetic opioid, diacetyl derivative of morphine prepared 
from opium for the illegal drug trade. Heroin is most commonly administered 
intravenously and by other parenteral routes, but may also be smoked. Heroin and 
6-acetylmorphine appear in oral fluid within 2 minutes of administration. Drug and 
metabolite concentrations in oral fluid are generally similar to blood concentrations 
following intravenous administration, but may be substantially higher than blood 
when smoked. Elevated drug and metabolite concentrations following smoking are 
probably a consequence of residual drug deposited in the oral cavity. Thirty to sixty 
minutes after heroin is smoked, concentrations in oral fluid diminish considerably 
and begin to reflect blood concentrations. If 6-acetylmorphine and morphine are 
detected, the use of heroin (and not morphine) can be confirmed.
MORPHINE: a natural opiate alkaloid isolated from the plant Papaver som-
niferum; it is also a metabolite of heroin and codeine. Following parenteral admin-
istration, morphine appears rapidly in saliva. Cone [48] reported an approximate 
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45-minute delay in equilibration of morphine concentrations in saliva compared to 
plasma following intramuscular administration of 10- and 20-mg doses; thereafter, 
saliva concentrations paralleled plasma concentrations. Morphine can be detected 
in oral fluid following intravenous administration, the smoking of heroin and 
poppy seed ingestion. Positive tests for morphine and codeine (with higher codeine 
concentration) implies codeine use.
CODEINE: a naturally occurring phenanthrene alkaloid and opioid agonist. It 
appears to be most commonly taken orally. While it is not a metabolite of morphine, 
it is metabolised by oxidation to morphine and norcodeine and by conjugation. 
Kim et al. [52] demonstrated that following oral administration of 60 and 120 mg, 
codeine appeared in oral fluid within an hour and reached maximum concentration 
in approximately 1.6–1.7 hours. Concentrations in oral fluid correlated significantly 
with plasma concentration and were three to four times higher in oral fluid than 
plasma. Codeine could be detected in oral fluid for approximately 21 and 7 hours at 
cut-off concentrations of 2.5 and 40 ng/mL, respectively. Following intramuscular 
codeine of 60 and 120 mg, codeine appeared rapidly in oral fluid and reached 
maximal concentrations in 0.5–0.75 hours. A positive test result for codeine and 
morphine generally indicates codeine use.
METHADONE: a synthetic opioid used widely as an analgesic as well as in 
maintenance therapy for persons with opioid dependency. Methadone undergoes 
extensive metabolism in the liver to form cyclic metabolites, 2-ethylidene-1,5-di-
methyl-3, 3-diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3-diphenylpyrro-
lidine (EMDP), and other minor metabolites. Methadone and EDDP appear rapidly 
in oral fluid and correlate with plasma concentrations. Therefore, the confirmed 
presence of oxidative metabolites such as EDDP and EMDP in oral fluid would be 
useful to substantiate use.
BUPRENORPHINE: an orally available, semisynthetic opioid analgesic, used 
as a pain reliever and in the management of opioid dependence. Following sub-
lingual administration, buprenorphine reaches maximal plasma concentrations 
in 1.3–1.6 hours. Its main metabolite is norbuprenorphine. Cone [48] reported 
measurements of buprenorphine in saliva following intramuscular and sublingual 
administration of single doses of buprenorphine. Drug concentrations in saliva 
were substantially lower than plasma at all times following intramuscular admin-
istration and were substantially higher following sublingual administration. The 
low S/P ratio following intramuscular administration is probably due to the high 
fraction of drug that is protein-bound in plasma. Close correspondence between 
saliva and plasma buprenorphine concentrations was observed in subjects who 
administered buprenorphine sublingually on a daily or every-other-day basis. If the 
oral fluid test reveals buprenorphine ≤ norbuprenorphine, this suggests chronic 
buprenorphine use.
4.3 Quality assurance of the analysis
Drug testing laboratories must implement a quality management system that 
includes all aspects of the testing process, such as sample reception, chain of cus-
tody, safety and reporting of results, screening and confirmation tests, certification 
of calibrators and controls, and validation of analytical procedures.
Hence, the laboratory should remain constantly updated on the evolution of 
analytical techniques, whether for finding new drugs or responding to requests 
for investigations concerning narcotic and pharmacological drugs. A highly quali-
fied analytical chemical-toxicological laboratory depends on ISO/IEC 17025 [53] 
accreditation standards and procedures to demonstrate that it operates competently 
and generates valid results. These standards are agreed by experts the world over, 
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thus promoting confidence in the work of accredited laboratories and other bodies, 
on national and international levels, and facilitating cooperation between them. 
With ISO certification, results are more widely accepted between countries without 
the need for further testing, consequently improving international trade.
Of course, the benefits of advanced equipment in the chemical-toxicological 
laboratory go hand in hand with the expertise of qualified personnel with specific 
competence and adequate scientific training (not restricted to the analytical 
chemical field). Only through this combination (state-of-the-art tools plus qualified 
personnel) will it be possible to develop new analytical methodologies in the field 
of toxicological-forensic analysis and respond to administrative, criminal and social 
needs imposed by the legal system.
4.3.1 Validation of an analytical method for the detection of drugs in saliva
The validation of analytical methods includes procedures designed to establish 
that a particular method, used for the identification and/or quantification of an 
analyte in a given biological matrix, is reliable and reproducible. It is a question 
of demonstrating that the performance characteristics of the method meet all the 
requirements for its intended purpose and application. Any analysis methodology 
used routinely by the laboratory must be previously validated according to interna-
tionally agreed procedures [17].
For the most commonly used screening tests, validation procedures are not 
usually necessary as the method is validated by the manufacturer. In any case, the 
analysis kit includes calibrators and controls which are to be inserted into each 
batch of samples to be analysed in order to verify the accuracy and precision of the 
analyses (according to predetermined target values). In the event that changes are 
introduced which deviate from the manufacturer’s instructions (for example, the 
biological matrix used is not the one indicated by the manufacturer, variation of the 
quantification limit, etc.) the laboratory must carry out a complete validation of 
the method/modified kit. It is best to fully respect the instructions provided by the 
manufacturer in the use of a kit, or in any case modifications should only be carried 
out in cases where it is not possible to use other methods.
The analysis methodology can be used routinely by the laboratory if the calcu-
lated validation parameters fall within the limits established by the relevant inter-
national directives [54].
The use of a good internal quality programme guarantees the reliability of the 
analytical results and avoids any random errors that may occur in the analytical 
and/or pre- or post-analytical phase that may affect the accuracy of the result.
The laboratory must participate in appropriate external quality assessment 
programmes. Analytical performances outside the criteria established by the External 
Quality Assessment (EQA) programme must be promptly corrected. The choice of 
one programme over another must be made on the basis of the best scientific evidence 
obtainable. Participation may concern the identification of classes of substances or 
individual substances and quantification in the case of confirmatory analyses accord-
ing to the legal cut-offs or established by the management body of the programme.
In the case of screening tests, the expression of the results is generally in terms 
of “positive” or “negative”. In the case of confirmatory analysis, it is necessary to 
provide not only qualitative but also quantitative data, namely the concentration 
detected according to a given calibration curve for the analyte identified in the 
saliva sample. The results of participation in the EQA are useful for the laboratory 
director and staff in helping to gauge the performance of the laboratory. In the 
event of errors, it is important to identify the causes and implement corrective 
actions that prevent them from recurring.
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4.3.2 The activity of the toxicology laboratory for forensic purposes
When the presence of drugs is confirmed in oral fluid, the person under investi-
gation may request the counter-analysis of another aliquot (B) of the saliva sample. 
This second test can be performed at the same laboratory that analysed the first 
aliquot (A) of the saliva sample or at another laboratory chosen by the subject in 
question. Aliquot B must be accompanied by a chain of custody form and include 
information regarding the results of the original analysis and the cut-offs used. 
Any laboratory that conducts analysis on aliquot B of the saliva sample must have 
documentation to demonstrate the use of validated analysis methodologies that 
meet the precision and accuracy criteria appropriate to the required analyses. It is 
crucial to guarantee the chain of custody [55], a documented procedure designed 
to ensure the authenticity, integrity and traceability of a sample from the moment 
of collection to its disposal. Following the proper chain of custody protocol is 
fundamental in the reconstruction process and ensures that the sample can be 
located at any point, unequivocally identified, stored correctly under the right 
conditions, and protected from tampering and voluntary or involuntary adultera-
tions in all phases. Documentation of the chain of custody must also record every 
movement and manipulation of the sample, on which dates and under whose care. 
In the judicial field, the chain of custody is deemed broken in any of the following 
scenarios (these shortcomings will lead to dispute and may even constitte instances 
of mystification):
• Missing or non-identical barcodes.
• Missing documentation (supposed to be attached).
• Absence of the informed consent of the person subjected to analytical 
assessment.
• Broken or tampered safety seals on sample containers or transport container.
• Absence of security seals.
• Insufficient sample volume for testing.
• Containers not intact and evident loss of sample.
On the basis of what has been said thus far, it is evident that laboratory staff are 
required to fulfil many responsibilities, with potential repercussions in the forensic 
field in the event of proven professional malpractice. It is therefore necessary to:
• define the type of services that can be provided (screening analysis and 
confirmation analysis), the suitability of resources and the guaranteed level of 
safety and reliability;
• ensure the availability of sufficient, adequately trained staff with the necessary 
experience to monitor and conduct the required laboratory tests (specifically, 
the analysis of substances of abuse on saliva samples);
• assure the competence of laboratory staff, document in-service training, 
validate the analytical method, and re-evaluate work performance;
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• provide the personnel of the laboratory with access to the complete, updated 
Standard Operating Procedures (SOP) manual;
• maintain an internal quality control programme which ensures that the analyses 
are performed correctly and that the results of the tests are communicated in 
compliance with SOPs;
• participate in appropriate External Quality Assessment (EQA) schemes;
• maintain acceptable analytical performance for all analysis methodologies 
applied in the laboratory;
• guarantee and document the validity, reliability, accuracy, precision and 
performance characteristics of each analysis and each analysis system;
• ensure that the necessary corrective actions are taken to maintain laboratory 
operation and performance at satisfactory levels (e.g. when a quality control 
system indicates non-compliance with performance specifications, or in 
response to errors in reporting results or in the analysis of the results of an 
EQA); the analytical results must not be reported until all the appropriate 
corrective actions have been taken.
In this context, the forensic toxicologist clearly has a fundamental role, with the 
responsibility of interpreting the analytical results of tests for substances of abuse in 
oral fluid at the request of a Legal Authority, competent doctor, potential customer 
or designated expert representative.
5. Conclusion
Oral fluid testing for drugs of abuse offers significant advantages. A saliva 
sample can be collected under direct observation with reduced risk of adultera-
tion and substitution and in a less embarrassing or unpleasant manner than urine 
or blood collection. As oral fluid collection is non-invasive, most people find the 
procedure more acceptable than having to provide other biological matrices, and 
suitable hygiene conditions can be respected while the donor is under the collector’s 
observation.
By providing an estimate of the actual circulating amount, the measurement of 
a drug concentration in oral fluid can be used for the determination of intoxication. 
In fact, measurements of oral fluid drug concentrations will usually be of value 
only if they accurately reflect the plasma level. Therefore, before designing a useful 
model for the salivary secretion of drugs, it is necessary to constantly update infor-
mation about the relationship between the saliva concentration level of each drug 
and its plasma concentration level, the mechanisms by which drugs enter oral fluid, 
and also the effect on salivary flow rate, production in the salivary glands, and the 
nature of any protein binding in the saliva.
It is very useful to know the limitations and possibilities of salivary analysis 
in forensic and diagnostic fields. Standardisation of the conditions for collection 
of oral fluid is strictly essential for achieving reliability and interpretation of the 
data. Furthermore, appropriate cut-off concentrations need to be established in 
the development of guidelines for oral fluid testing [56]. In future research, the 
mechanisms by which drugs enter the saliva must be clarified more adequately. 
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These considerations are matters of ongoing discussion in the scientific community, 
in particular the proposed initial screening and confirmatory cut-offs.
When an oral fluid test is performed on a corpse, the forensic pathologist must 
be accompanied by a toxicologist for the interpretation of the analytical data. It 
should also be noted that significant ethical issues are involved in the study of many 
licit and illicit drugs that preclude or limit the study of their short- and long-term 
effects under “real-world use” conditions, which means that some knowledge will 
always remain inaccessible.
Finally, there are some open questions and limitations to consider in salivary 
analysis for forensic purposes. Despite a substantial number of clinical studies on 
drug disposition in oral fluid, many psychoactive drugs have not been studied. 
Benzodiazepines and barbiturates and some opioid products have received limited 
or no evaluation in oral fluid; meanwhile, there is a lack of controlled dosing studies 
of hallucinogens in humans. Furthermore, the dynamic nature of oral fluid, espe-
cially its pH, can substantially affect drug concentrations of basic drugs. It follows 
that, to date, in a forensic context, the result of an oral fluid test remains question-
able, not only for reasons strictly connected to pharmacokinetic and metabolic 
characteristics, but also for purely analytical reasons:
a. difficulty in applying standardised procedures for sampling;
b. frequent smallness of the sample compared to conventional matrices (e.g. blood) 
with consequent limitations in terms of multiclass analyses and sampling for 
counter-analyses;
c. variability of the relationship between salivary and blood concentrations as a 
function of the variability of salivary pH;
d. possibility of contamination of the oral cavity after ingestion of a substance via 
intranasal use or inhalation.
e. laboratory deficiencies and/or incorrect application of the analytical 
procedures.
Therefore, salivary analysis for forensic purposes, now and in the future, neces-
sarily requires a union between highly qualified personnel (able to apply analytical 
methods and interpret results in the light of up-to-date scientific knowledge) and 
toxicological laboratories equipped with state-of-the-art instrumentation.
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